CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, f ...

CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate i ...

Core Insights - Apyx Medical Corporation is participating in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 [1] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System [2] - The company utilizes Helium Plasma Platform Technology, which provides controlled heat to tissue, enhancing surgical outcomes [2] - Renuvion and J-Plasma are supported by over 90 clinical documents, demonstrating their effectiveness in both cosmetic and hospital surgical markets [2] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple functionalities, including fat removal and tissue contraction, into a single platform [2] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [2]

Financial Results - Apyx Medical Corporation reported preliminary revenue results for Q4 and the year ended December 31, 2025[5] - The press release detailing these results was issued on January 12, 2026[5] Company Information - The company is listed on the Nasdaq Global Select Market under the trading symbol APYX[3] - Apyx Medical Corporation is incorporated in Delaware and has an Employer Identification Number of 11-2644611[2] Report Details - The report includes a cover page interactive data file as part of its exhibits[8] Management - Matthew Hill serves as the Chief Financial Officer, Secretary, and Treasurer of Apyx Medical Corporation[11]

Core Viewpoint - Apyx Medical Corporation reported preliminary revenue results for Q4 and full year 2025, highlighting strong growth driven by the commercial launch of the AYON Body Contouring System and increased demand in the surgical aesthetics market [1][4]. Preliminary Fourth Quarter 2025 Revenue Summary - Total revenue for Q4 2025 is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year [7]. - Surgical Aesthetics revenue for Q4 2025 is expected to be in the range of approximately $16.6 to $16.8 million, reflecting an increase of approximately 38% year-over-year [7]. - OEM revenue for Q4 2025 is expected to be approximately $2.4 million, indicating an increase of approximately 13% year-over-year [7]. Preliminary Full Year 2025 Revenue Summary - Total revenue for the full year 2025 is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year [7]. - Surgical Aesthetics revenue for the full year 2025 is expected to be in the range of approximately $45.2 to $45.4 million, showing an increase of approximately 17% year-over-year [7]. - OEM revenue for the full year 2025 is expected to be approximately $7.5 million, reflecting a decrease of 21% year-over-year [7]. Industry Context - The commercial launch of AYON has generated immediate momentum, contributing to a strong fourth quarter performance, with a noted increase in aesthetic surgical procedures in the U.S. driven by the adoption of GLP-1 therapies leading to significant patient weight loss [4]. - The company is positioned to capitalize on the positive industry momentum in the surgical aesthetics market [4]. Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion® and the AYON Body Contouring System™ [5]. - The AYON Body Contouring System is an FDA-cleared, surgeon-designed platform that integrates various capabilities for comprehensive body contouring treatments [5]. - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to innovation in the cosmetic surgery market [5].

Core Insights - Apyx Medical Corporation has received regulatory approval for the Apyx One console and plans to launch commercial sales in South Korea, with initial orders expected in Q4 2025 [1][3] - The Apyx One console features a 3-in-1 energy system that allows for advanced surgical procedures, including Renuvion technology, and is designed for ease of use with adaptive touch screens and energy quantification [2] - The cosmetic surgery market in South Korea is projected to grow from $1.7 billion in 2024 to over $3.9 billion by 2033, indicating a significant opportunity for Apyx Medical's body contouring technology [3] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System, which provide controlled heat to tissue for surgical procedures [4] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the versatility and precision of body contouring treatments [4]

Core Viewpoint - Apyx Medical Corporation has announced a public offering of 2,762,431 shares of its common stock at a price of $3.62 per share, with the offering expected to close on or about November 19, 2025 [1][2]. Group 1: Offering Details - The offering is underwritten by Lucid Capital Markets, which is acting as the sole book-running manager [2]. - The company has granted the underwriter a 45-day option to purchase an additional 414,365 shares at the public offering price [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 2: Regulatory and Documentation - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on December 2, 2022 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which provide innovative solutions in cosmetic surgery [6]. - The company’s technologies, including Helium Plasma Platform Technology, are supported by over 90 clinical documents, demonstrating their effectiveness [6]. - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the treatment options available to surgeons [6].

Core Viewpoint - Apyx Medical Corporation is initiating an underwritten public offering of its common stock, subject to market conditions, with no assurance on the completion or terms of the offering [1]. Group 1: Offering Details - Lucid Capital Markets is the sole book-running manager for the offering [2]. - The offering is made under a shelf registration statement filed with the SEC on November 22, 2022, and declared effective on December 2, 2022 [2]. Group 2: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which are designed to enhance surgical outcomes [5]. - The Renuvion and J-Plasma technologies provide controlled heat to tissue, supported by over 90 clinical documents [5]. - The AYON Body Contouring System is FDA-cleared and integrates multiple capabilities for comprehensive body contouring treatments [5].

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may be blocked from proceeding if an ad-blocker is enabled [1]

Revenue and Sales Performance - Total revenue increased by 12.1%, or approximately $1.4 million, for the three months ended September 30, 2025, compared to the same period in 2024[75]. - Surgical Aesthetics segment sales increased 19.1%, or approximately $1.8 million, for the three months ended September 30, 2025, driven by the commercial launch of AYON and increased sales of single-use handpieces[75]. - OEM segment sales decreased 17.6%, or approximately $0.4 million, for the three months ended September 30, 2025, due to lower sales volume to existing customers[75]. - Surgical Aesthetics sales increased 8.0%, or approximately $2.1 million, for the nine months ended September 30, 2025, compared to the same period in 2024[76]. - OEM segment sales decreased 31.4%, or approximately $2.3 million, for the nine months ended September 30, 2025, due to decreased sales volume to existing customers[76]. Profitability and Margins - Gross profit for the three months ended September 30, 2025, increased 19.3% to $8.3 million, with a gross margin of 64.4% compared to 60.5% for the same period in 2024[78]. - Gross profit for the nine months ended September 30, 2025, increased 3.2% to $21.0 million, with a gross margin of 62.5% compared to 60.2% in the prior year[80]. Cost Management and Expenses - The company reduced its workforce by nearly 25% in November 2024, estimating annualized future cost savings of approximately $4.3 million[69]. - The company plans to reduce annual operating expenses below $40 million in 2025 through various cost-saving measures[69]. - Research and development expenses decreased 38.7% for the nine months ended September 30, 2025, totaling $2.4 million, primarily due to lower compensation and benefits costs[82]. - Professional services expense decreased 14.4% for the nine months ended September 30, 2025, amounting to $4.6 million, driven by reductions in physician and marketing consulting expenses[84]. - Salaries and related expenses decreased 27.5% for the nine months ended September 30, 2025, totaling $9.3 million, due to lower headcount and stock-based compensation[86]. - Selling, general and administrative expenses decreased 20.3% for the nine months ended September 30, 2025, amounting to $11.2 million, primarily due to lower travel and meeting costs[89]. Cash Flow and Financial Position - At September 30, 2025, cash and cash equivalents were approximately $25.1 million, down from $31.7 million at December 31, 2024[93]. - Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $5.5 million, a decrease from $15.5 million in the prior year[94]. - The company had purchase commitments totaling approximately $4.4 million, expected to be purchased within the next twelve months[101]. Compliance and Risk Management - As of September 30, 2025, the company was in compliance with the financial covenants of the Perceptive Credit Agreement, which includes revenue targets for the Surgical Aesthetics segment[98]. - The company has adjusted its accounts receivable allowance due to economic uncertainty in the capital equipment market, particularly in the aesthetic space, resulting in extended credit terms granted to customers[104]. - The company maintains a reserve for uncollectible accounts receivable, analyzing historical bad debt experience and the composition of outstanding receivables[104]. - There are no off-balance sheet arrangements currently in place[106]. - The company has not identified any changes in internal control over financial reporting that materially affect its operations[111]. - The management's disclosure controls and procedures were deemed effective as of September 30, 2025[110]. - There have been no material changes to the risk factors previously described in the Annual Report for the fiscal year ended December 31, 2024[115]. - The company has recorded liabilities for litigation contingencies when a loss is known or considered probable, requiring significant judgment[105]. - The company has not reported any unregistered sales of equity securities or defaults upon senior securities[116][117]. - The company has not disclosed any new products, technologies, market expansions, or acquisitions in the current report[108]. - There are no significant quantitative or qualitative disclosures about market risk applicable to the company[109]. Product Development - The AYON Body Contouring System™ received 510(k) clearance from the FDA on May 13, 2025, and the commercial launch commenced in September 2025[66].